Form 4: Mineralys Therapeutics Director Receives Equity Grant

An insider associated with RA Capital Management, a significant shareholder and director of Mineralys Therapeutics, was granted restricted stock units and stock options as part of compensation.

Summary

• Dr. Derek DiRocco, a Partner of RA Capital Management, L.P. and a director of Mineralys Therapeutics, Inc., was granted 6,200 Restricted Stock Units (RSUs) on February 19, 2026.
• Each RSU represents a contingent right to receive one share of common stock upon vesting, which occurs in one annual installment following the grant date.
• Dr. DiRocco was also granted 8,300 stock options on February 19, 2026, with an exercise price of $28.06 per share.
• These stock options vest in 12 substantially equal monthly installments following the grant date and expire on February 19, 2036.
• The RSUs and stock options are held by Dr. DiRocco for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P.
• RA Capital Management, L.P. and its affiliates collectively hold 5,456,521 shares of common stock directly by RA Capital Healthcare Fund, L.P. and 1,867,229 shares directly by RA Capital Nexus Fund III, L.P.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard director compensation and continued alignment of a significant institutional investor's representative with the company's performance.

Positives

• The equity grants align the interests of a key director, representing a significant institutional investor, with the long-term performance and shareholder value of Mineralys Therapeutics.
• The grants are a standard form of compensation, indicating continued commitment from a director associated with a major shareholder.

Negatives

• The grants are future-dated compensation events rather than immediate open market purchases, which might signal stronger direct insider confidence.
• Potential future dilution for existing shareholders upon the vesting of RSUs and exercise of stock options.

Future Outlook

The 6,200 Restricted Stock Units are scheduled to vest in one annual installment following the February 19, 2026 grant date. The 8,300 stock options will vest in 12 substantially equal monthly installments following the same grant date, indicating future share issuance and potential exercise activity.

Management Comments

• "Restricted Stock Units (RSUs) are granted to Dr. Derek DiRocco for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant."
• "Dr. Derek DiRocco is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the RSUs and the options for the benefit of the Fund and the Nexus Fund III."
• "Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon settlement of the RSUs or exercise of the options, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser."

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biotechnology and pharmaceutical industries, aligning leadership incentives with long-term company performance and shareholder value. This particular filing highlights the compensation structure for a director representing a significant institutional investor, which is common for venture-backed or growth-stage companies.

Comparison to Industry Standards

• Equity compensation for board members, including RSUs and stock options, is a common practice across industries, particularly in growth-oriented sectors like biotech.
• The structure, where a director from an investment firm holds equity for the benefit of the fund, is typical for venture capital or institutional investor representatives on portfolio company boards.
• Comparable companies within the S&P Biotech Select Industry Index (XBI) frequently utilize similar equity compensation structures for directors and executives, often with multi-year vesting schedules to promote long-term commitment and retention.

Related Party Transactions

• Dr. Derek DiRocco, a Partner of RA Capital Management, L.P. (a 10% owner and director of Mineralys Therapeutics), received RSUs and stock options.
• These equity grants are held by Dr. DiRocco for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P., with Dr. DiRocco obligated to turn over net proceeds to RA Capital Management, L.P., offsetting advisory fees.

Stakeholder Impact

• Shareholders: Potential for future dilution from the issuance of shares upon RSU vesting and option exercise. The grants also reinforce alignment of a significant institutional investor's representative with the company's long-term performance.
• Employees: No direct impact mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Next Steps

• Vesting of 6,200 Restricted Stock Units in one annual installment following February 19, 2026.
• Vesting of 8,300 stock options in 12 substantially equal monthly installments following February 19, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director representing a major institutional investor. While it signals continued alignment of interests, it does not present new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment stance. It's a standard compensation event.

Keywords

Mineralys Therapeutics, MLYS, RA Capital Management, Insider Transaction, Form 4, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation